Cargando…
Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept
Intravitreal anti-VEGF (anti-vascular endothelial growth factor) biologics have revolutionized the pharmacological management of chorioretinal diseases. However, the systemic adverse events such as stroke or bleeding are the concerns for many patients and physicians. The mechanism to develop these s...
Autores principales: | Yi, Quan-Yong, Chen, Li-Shuang, Shen, Yu, Liao, Yan-Hong, Wang, Yan-Yan, Yang, Jie, Jin, Yuanhui, Cheng, Lingyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668998/ https://www.ncbi.nlm.nih.gov/pubmed/34903819 http://dx.doi.org/10.1038/s41598-021-03335-3 |
Ejemplares similares
-
The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy
por: Mao, Jianbo, et al.
Publicado: (2019) -
Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy
por: Wang, Weiwei, et al.
Publicado: (2023) -
Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy
por: Ding, Yuzhi, et al.
Publicado: (2023) -
Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
por: Gao, Caifeng, et al.
Publicado: (2023) -
Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China: Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization
por: Nie, Xin, et al.
Publicado: (2021)